Overview

Effect of Low Dose Bortezomib on Bone Formation in Smoldering Myeloma Patients

Status:
Terminated

Trial end date:
2014-09-01

Target enrollment:

Participant gender:

Summary

OBJECTIVES - Primary: To evaluate the bone anabolic effect of bortezomib in patients with smoldering myeloma. - Secondary: To evaluate the effect of bortezomib on the natural history of smoldering myeloma.

Phase:

Phase 2

Details

Lead Sponsor:

University of Utah

Collaborator:

Millennium Pharmaceuticals, Inc.

Treatments:

Bortezomib